Ironwood Pharmaceuticals (IRWD, Financial) experienced a significant stock price decline of 5.30%, trading at $4.20 per share. The trading volume reached 885,652 shares with a turnover rate of 0.55% and a price fluctuation of 7.34%. Recent financial reports show revenue of $91.59 million, net profit of $3.65 million, and earnings per share of $0.02. The company's price-to-earnings ratio stands at -421.50. Among six rating institutions, 83% recommend buying, while 17% suggest holding the stock.
Within the pharmaceutical sector, which rose by 0.31%, notable performers included Procaps Group S.A., Scynexis, Inc., and Biofrontera Inc. Stocks with high turnover rates were Nature's Sunshine Products, Suzhou Suxuantang, and Painreform Ltd. Biofrontera Inc. and Medicus Pharma Ltd. showed significant price fluctuations.
Ironwood Pharmaceuticals specializes in both branded and generic drugs, focusing on unmet medical needs such as irritable bowel syndrome with constipation and uncontrolled gout-related hyperuricemia. The company aims to grow through licensing, commercial agreements, and acquisitions.
